1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer
Abstract
MNA contributes to the immune suppression of T cells and represents a potential immunotherapy target to treat human cancer.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 22, 2021
- Source ID
- 10.1126/sciadv.abe1174
Entities
People
- Abigail E. Ellis
- Bertrand Allard
- Brad H Nelson
- Brenna Pauly
- Elaine Y. Liu
- Gillian Carleton
- John Stagg
- Julian J. Lum
- Julian Smazynski
- Kelsey S. Williams
- Lauren G. Zacharias
- Marisa K. Kilgour
- Peter H. Watson
- Phineas T. Hamilton
- Ralph J DeBerardinis
- Russell G Jones
- Ryan D. Sheldon
- Sarah Keyes
- Sarah Macpherson
Organizations
- BC Cancer Agency
- BC Cancer Foundation
- Canada Foundation for Innovation
- Canadian Institutes of Health Research
- Institut du cancer de Montréal
- United States Department of Defense
- University of British Columbia
- University of Texas Southwestern Medical Center
- University of Victoria
- Université de Montréal
- Van Andel Institute